 |
sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] |
|---|---|
| Trade Name | |
| Orphan Indication | Pancreatic Cancer |
| USA Market Approval | USA |
| USA Designation Date | 2017-06-08 00:00:00 |
| Sponsor | Intezyne Technologies, Inc.;3720 Spectrum Boulevard, Suite 104;Tampa, Florida, 33612 |
